Skip to Main Content
  • McGraw Hill Medical
  • McGraw Hill Medical
    • Umbrella Logo Dropdown McGraw Hill Medical Home
    • Explorar m?s sitios
      AccessAnesthesiology
      AccessAPN
      AccessBiomedical Science
      AccessCardiology
      AccessDermatologyDxRx
      AccessEmergency Medicine
      AccessHemOnc
      AccessMedicina
      AccessMedicine
      AccessNeurology
      AccessObGyn
      AccessPediatrics
      AccessPharmacy
      AccessPhysiotherapy
      AccessSurgery
      Case Files Collection
      Clinical Sports Medicine Collection
      F.A. Davis AT Collection
      F.A. Davis PT Collection
      JAMAevidence
      Murtagh Collection
      OMMBID
      Pharmacotherapy Principles & Practice
  • Soporte técnico
    • Recursos para usuarios
    • ¿Quiénes somos?
    • Contáctenos
    • Enviar retroalimentación
  • Suscripciones
Iniciar sesión Sign In

Inicio de sesión MyAccess

Crear un perfil gratuito MyAccess
¿Olvidó su contraseña?
¿Olvidó su nombre de usuario?

Acerca de MyAccess

Si su institución se suscribe a este recurso y usted no tiene un perfil MyAccess, por favor póngase en contacto con el departamento de referencia de su biblioteca para obtener información sobre cómo acceder a este recurso desde fuera del campus.

Leer más
Inicie sesión mediante OpenAthens
Inicie sesión mediante Shibboleth
AccessMedicina home page Home
Navigation Menu Search Menu
  • Libros
  • Referencia rápida
    • Diagnosaurus®
    • Pruebas de diagnóstico
    • Guías
    • Calculadoras
    • 2 Minute Medicine®
    • Acrónimos
  • Fármacos
    • Monografías de fármacos
    • Interacción de fármacos
  • Multimedia
    • Animaciones 3D
    • Anatomía 3D - Módulos
    • Anatomía 3D - Desafío de anatomía
    • COVID-19
    • Harrison Podclass
    • Vídeos por aparatos y sistemas
    • Lecciones de farmacología
    • Harrison Animaciones de fisiopatología
    • Medicina de urgencias
  • Infografías
  • Casos
    • Casos
    • Desequilibrios hidroelectrolíticos/trastornos
    • Fisiopatología
    • Harrison Casos. Desafío visual
  • Autoevaluación
    • Por Recurso
    • Flashcards
  • Educación del paciente
     
    Acerca de búsqueda
    Enable Autosuggest
    ¡Bienvenido!

    Ha creado correctamente un Perfil de MyAccess para
    alertsuccessName.

    Las características de MyAccess incluyen:
    • Acceso remoto
    • Favoritos
    • Guardar figuras en PowerPoint
    • Descargar cuadros como archivos PDF
    Ir al Panel de control  Cerrar
    Inicio > 2 Minute Medicine® > Dermatology >
    Book cover
    Editors and Contributors

    Evening-dose immune checkpoint inhibitors were associated with worse survival outcomes

    by Kassandra McFarlane, Samuel Chan
    +

    Originally published by 2 Minute Medicine® (view original article). Reused on AccessMedicine with permission.

    +

    1. Receiving at least 20% of infusions after 1630h was associated with decreased overall survival in patients treated with immune-checkpoint inhibitors for metastatic melanoma

    +

    2. Both progression-free survival and disease response were worse in patients receiving at least 20% of infusions after 1630h.

    +

    Evidence Rating Level: 2 (Good)

    Study Rundown:

    +
    +

    The immune system has circadian rhythm variability, such that weaker responses are noted in the evening. This study examined the outcome on overall survival (OS), progression-free survival (PFS), and disease response in patients receiving checkpoint inhibitor infusion treatment for stage IV melanoma at different times of the day. Evening was considered to begin at 1630h. Patients receiving a minimum of 20% of their treatment after 1630h were found to have reduced OS, with 5 year OS rates for these patients at 49% as compared to 68% for patients who had less than 20% evening treatments. PFS at 1 year in patients with a greater number of evening infusions was 40%, compared with 56% for patients with fewer evening infusions. Additionally, there was a decreased rate of disease response for patients receiving more evening infusions compared to patients receiving less (22% vs. 34%). The most common adverse events associated with checkpoint inhibitor treatment were colitis, hepatitis, and hypophysitis. No deaths due to treatment were reported. Limitations to the study include the retrospective format, the exclusion of patients receiving less than 4 infusions, as well as restriction of the study to one site. Additionally, the study results may not be applicable in all clinical scenarios due to variation of treatment sequence and duration for each patient. Overall, patients with stage IV melanoma may benefit from daytime, rather than evening, infusions of immune checkpoint inhibitors.

    +

    Click to read the study in The Lancet Oncology

    +

    Click to read an accompanying editorial in The Lancet Oncology

    +

    Relevant Reading: Circadian rhythms in adaptive immunity

    In-Depth [retrospective cohort]:

    +
    +

    This retrospective cohort study based out of one site in the United States recruited 299 adult patients with stage IV melanoma who received at least 4 infusions of immune checkpoint inhibitor therapy (nivolumab, pembrolizumab, ipilimumab, or a combination). Total and 5 year overall survival (OS) were primary outcomes, with both progression-free survival (PFS) and disease response being secondary outcomes. Analysis of all 299 patients found a crude OS hazard ratio of 1.31 (95% confidence interval (CI), 1.00-1.71) for each additional 20% infusion received in the evening. A greater number of evening infusions was also associated with reduced PFS at 40% (95% CI, 30-54%) compared to those with fewer at 56% (95% CI, 50-63%). Disease response was also reduced in patients with more evening infusions (22%) compared to those with fewer (34%). Using a propensity score-matched analysis and multivariable adjustment, infusions in the evening were associated with a decreased OS (HR 2.04, 95% CI, 1.04-4.00, p = 0.038). Five year OS for patients receiving at least 20% of their treatment in the evening was 49% (95% CI, 31-76%) compared to 68% (95% CI, 53-86%) for patients with fewer than 20%. During treatment, 18% of 299 patients experienced colitis, 9% experienced hepatitis, and 5% had hypophysitis. No treatment related-deaths were recorded.

    +

    ©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

    Pop-up div Successfully Displayed

    This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

    Please Wait

    2MM Topics
    Dermatology
    Oncology

    AccessMedicina

    • Libros
    • Referencia rápida
    • Diagnosaurus®
    • Pruebas de diagnóstico
    • Guías
    • Calculadoras
    • 2 Minute Medicine®
    • Acrónimos
    • Fármacos
    • Monografías de fármacos
    • Interacción de fármacos
    • Multimedia
    • Animaciones 3D
    • Anatomía 3D - Módulos
    • Anatomía 3D - Desafío de anatomía
    • COVID-19
    • Harrison Podclass
    • Vídeos por aparatos y sistemas
    • Lecciones de farmacología
    • Harrison Animaciones de fisiopatología
    • Medicina de urgencias
    • Infografías
    • Casos
    • Casos
    • Desequilibrios hidroelectrolíticos/trastornos
    • Fisiopatología
    • Harrison Casos. Desafío visual
    • Autoevaluación
    • Por Recurso
    • Flashcards
    • Educación del paciente
    • Acerca de

    McGraw Hill Medical

    • Sites
    • AccessAnesthesiology
    • AccessAPN
    • AccessBiomedical Science
    • AccessCardiology
    • AccessDermatologyDxRx
    • AccessEmergency Medicine
    • AccessHemOnc
    • AccessMedicina
    • AccessMedicine
    • AccessNeurology
    • AccessObGyn
    • AccessPediatrics
    • AccessPharmacy
    • AccessPhysiotherapy
    • AccessSurgery
    • Case Files Collection
    • Clinical Sports Medicine Collection
    • F.A. Davis AT Collection
    • F.A. Davis PT Collection
    • JAMAevidence
    • Murtagh Collection
    • OMMBID
    • Pharmacotherapy Principles & Practice
    • Soporte técnico
    • Recursos para usarios
    • ¿Quiénes somos?
    • Contáctenos
    • Enviar retroalimentación
    • Suscripciones
    • Suscripciones Institucionales
    • Suscripciones individuales
    McGraw Hill

    Copyright © McGraw Hill
    Todos los derechos reservados.
    Su dirección IP es 3.236.70.233
    Términos de uso   •  Aviso de privacidad   •  Anuncio   •  Soporte de Navegador

    Silverchair
    Arriba
    >
    Este sitio usa cookies. Al continuar navegando en este sitio, usted acepta nuestro uso de cookies. Más información Cerrar